Diagnosing Adverse Drug Reactions Registry
- Conditions
- Genetics of Drug Metabolism
- Registration Number
- NCT01970709
- Lead Sponsor
- Renaissance RX
- Brief Summary
This multicenter Registry is to assess whether the use of pharmacogenomic data results in a meaningful change in a subject's drug or dose regimen. In addition, the Registry will evaluate the relationship between adverse drug reactions (ADR) and genotype and assess resource utilization (emergency department visits and hospitalizations) associated with ADR.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 250000
- Subject has care coordinated at the treating physician's outpatient clinic;
- Subject has provided written informed consent;
- Subject is taking at least three (3) regularly scheduled medications, excluding as needed (PRN) medications, over the counter medications and nutritional supplements; two (2) of which are known to be affected by genetic allelic variation.
- Subject's treating physician has a clinical suspicion that the subject is experiencing adverse signs or symptoms related to a prescribed medication or is not achieving the intended effect from the medication.
- Subject has a history of chronic renal dysfunction, Chronic Kidney Disease Stage 4 or 5;
- Subject has a history of abnormal hepatic function within the last 2 years (INR >1.2 not attributable to anticoagulant medications, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) >1.5x normal, or suspected cirrhosis);
- Subject has a history of malabsorption (short gut syndrome);
- Subject has a history of any gastric or small bowel surgery;
- Subject is currently hospitalized;
- Subject is currently being treated with intravenous medication;
- Subject underwent prior pharmacogenomic testing with results reported within the last 12 months.
Subjects may be eligible within 60 days from the date of pharmacogenomic testing.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of meaningful change in drug regimen 60 days The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each subject when:
* A genotype known to affect a drug the subject is taking is identified, and
* The subject's treating physician makes at least one drug regimen change in concordance with the PharmD recommendations.
- Secondary Outcome Measures
Name Time Method Change in the regimen of drugs controlled by genes of interest over the 12 months prior to enrollment and change in the regimen of drugs controlled by genes of interest over the 60 days following receipt of pharmacogenetic test results. 60 days Number of ADR per month over the 12 months prior to enrollment and number of ADR per month over the 60 days following receipt of pharmacogenomic test results. 60 days Emergency department visits and hospitalizations 60 days Emergency department visits over the 12 months prior to enrollment, emergency department visits over the 60 days following receipt of test results, hospitalizations over the 12 months prior to enrollment, and hospitalizations over the 60 days following receipt of test results.
Frequency of genome-based PharmD recommendations to alter drug or dose. 60 days
Trial Locations
- Locations (49)
Edwards Lake Medical Center
🇺🇸Birmingham, Alabama, United States
Gerald Harris MD
🇺🇸Glendale, Arizona, United States
Holland Center for Family Health
🇺🇸Peoria, Arizona, United States
AZ Pain Center
🇺🇸Phoenix, Arizona, United States
Olga Voroshilovsky
🇺🇸Los Angeles, California, United States
Institute for Regenerative Medicine and Clinical Research
🇺🇸Pasadena, California, United States
Boulder Medical Center
🇺🇸Boulder, Colorado, United States
Prime Healthcare - Anthony Roselli MD
🇺🇸Avon, Connecticut, United States
Washington Pain Center
🇺🇸Washington, District of Columbia, United States
Continental Research Network
🇺🇸Doral, Florida, United States
Scroll for more (39 remaining)Edwards Lake Medical Center🇺🇸Birmingham, Alabama, United States